HOOKIPA Pharma Inc. (HOOK): Nasdaq/NYSE listing notice — HOOKIPA Pharma transfers listing to Nasdaq Capital Market to regain bid price compliance

HOOKIPA Pharma Inc.

Received Nasdaq approval to transfer common stock listing from Global Select Market to Capital Market effective Feb 1, 2024.
Granted a second 180-day compliance period until July 29, 2024 to meet $1.00 minimum bid price requirement.
Company must close at $1.00 per share for 10 consecutive business days to regain compliance.
If compliance not achieved by July 29, 2024, Nasdaq may delist the stock; Company may appeal.
Company intends to cure deficiency via a reverse stock split if necessary.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

HOOKIPA Pharma Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

from The Nasdaq Global Select Market tier to The Nasdaq Capital Market tier, as well as the Company’s request for a second 180-calendar day period, or until July 29, 2024 (the “Second Compliance Period”), to regain compliance with the $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). To regain compliance with such minimum price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The transfer of the listing of the Company’s Common Stock from The Nasdaq Global Select Market to The Nasdaq

View on SEC.gov

Browse all listing & compliance notices →

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-008825

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.